NASDAQ:CLGN CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis $0.43 -0.01 (-1.14%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$0.44 +0.00 (+0.74%) As of 07:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CollPlant Biotechnologies Stock (NASDAQ:CLGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CLGN alerts:Sign Up Key Stats Today's Range$0.38▼$0.4550-Day Range$0.29▼$0.7552-Week Range$0.27▼$4.98Volume38,608 shsAverage Volume87,258 shsMarket Capitalization$6.27 millionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingHold Company Overview CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards. CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues. These bioinks serve as scaffolds to support cell growth and tissue formation, targeting indications such as cartilage repair, orthopedic implants and breast reconstruction. The company’s preclinical pipeline extends into areas like tendon and ligament engineering, leveraging its collagen platform to address unmet needs in regenerative therapy. Founded in 2009 and headquartered in Rehovot, Israel, CollPlant maintains operations in the United States with offices in Bridgewater, New Jersey. The company has secured CE Mark approvals for several products in Europe and is pursuing additional regulatory clearances worldwide. Through strategic collaborations and licensing agreements, CollPlant aims to expand its global footprint across North America, Europe and Asia, partnering with device manufacturers and research institutions to accelerate product development. Under the leadership of President and Chief Executive Officer Yehiel Tal, CollPlant’s management team combines expertise in biotechnology, medical devices and pharmaceutical development. The company continues to invest in research, manufacturing capacity and strategic partnerships to advance its vision of providing sustainable, high-quality collagen solutions for the regenerative medicine market.AI Generated. May Contain Errors. Read More CollPlant Biotechnologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreCLGN MarketRank™: CollPlant Biotechnologies scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCollPlant Biotechnologies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialCollPlant Biotechnologies has a consensus price target of $11.50, representing about 2,544.9% upside from its current price of $0.43.Amount of Analyst CoverageCollPlant Biotechnologies has only been the subject of 1 research reports in the past 90 days.Read more about CollPlant Biotechnologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CollPlant Biotechnologies is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CollPlant Biotechnologies is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCollPlant Biotechnologies has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about CollPlant Biotechnologies' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.62% of the float of CollPlant Biotechnologies has been sold short.Short Interest Ratio / Days to CoverCollPlant Biotechnologies has a short interest ratio ("days to cover") of 0.47, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CollPlant Biotechnologies has recently increased by 22.49%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCollPlant Biotechnologies does not currently pay a dividend.Dividend GrowthCollPlant Biotechnologies does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentCollPlant Biotechnologies has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CollPlant Biotechnologies this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.Percentage Held by Insiders9.60% of the stock of CollPlant Biotechnologies is held by insiders.Percentage Held by Institutions21.69% of the stock of CollPlant Biotechnologies is held by institutions.Read more about CollPlant Biotechnologies' insider trading history. Receive CLGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLGN Stock News HeadlinesCollPlant Biotechnologies (CLGN) to Release Quarterly Earnings on ThursdayMay 14, 2026 | americanbankingnews.comAbbVie ends CollPlant deal and slashes workforce to cut costsApril 13, 2026 | msn.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 19 at 1:00 AM | Profits Run (Ad)CollPlant Issues Letter to ShareholdersApril 13, 2026 | prnewswire.comCOLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEMarch 26, 2026 | prnewswire.comCollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid RequirementMarch 24, 2026 | prnewswire.comCollPlant Biotechnologies Launches Redesigned Corporate WebsiteMarch 18, 2026 | prnewswire.comCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTSMarch 11, 2026 | prnewswire.comSee More Headlines CLGN Stock Analysis - Frequently Asked Questions How have CLGN shares performed this year? CollPlant Biotechnologies' stock was trading at $1.40 at the beginning of the year. Since then, CLGN stock has decreased by 68.9% and is now trading at $0.4348. How were CollPlant Biotechnologies' earnings last quarter? CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) released its quarterly earnings data on Wednesday, November, 26th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of $0.38 by $0.65. The firm earned $0.08 million during the quarter, compared to analysts' expectations of $16.52 million. CollPlant Biotechnologies had a negative net margin of 353.70% and a negative trailing twelve-month return on equity of 161.69%. When did CollPlant Biotechnologies IPO? CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager. How do I buy shares of CollPlant Biotechnologies? Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CollPlant Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include Enovix (ENVX), Rambus (RMBS), Compass Pathways (CMPS), Ginkgo Bioworks (DNA), Globant (GLOB), Luminar Technologies (LAZR) and Saia (SAIA). Company Calendar Last Earnings11/26/2025Today5/19/2026Next Earnings (Estimated)5/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CLGN's financial health is in the Red zone, according to TradeSmith. CLGN has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolNASDAQ:CLGN CIK1631487 Webwww.collplant.com Phone972732325600Fax972-73-232-5602Employees70Year Founded1981Price Target and Rating Average Price Target for CollPlant Biotechnologies$11.50 High Price Target$12.00 Low Price Target$11.00 Potential Upside/Downside+2,544.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.49 million Net Margins-353.70% Pretax Margin-484.56% Return on Equity-161.69% Return on Assets-109.44% Debt Debt-to-Equity RatioN/A Current Ratio2.53 Quick Ratio2.31 Sales & Book Value Annual Sales$2.37 million Price / Sales2.64 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book0.91Miscellaneous Outstanding Shares14,410,000Free Float13,031,000Market Cap$6.27 million OptionableOptionable Beta1.47 Social Links The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:CLGN) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CollPlant Biotechnologies Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share CollPlant Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
